Search research articles
Contact Us
Filters
Showing results (41-50 of 92) with videos related to
Page
of 10
Sort By:
Blood
|
January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Leukemia & Lymphoma
|
September 28, 2011
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia
Michael W Evans, Anthony D Sung, Ivana Gojo, et al.
British Journal of Haematology
|
August 10, 2007
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells
Kyu-Tae Kim, Kristin Baird, Sean Davis, et al.
British Journal of Haematology
|
March 16, 2007
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells
Li Li, Obdulio Piloto, Kyu-Tae Kim, et al.
Signal Transduction and Targeted Therapy
|
May 24, 2021
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
Ruiqi Zhu, Li Li, Bao Nguyen, et al.
Blood
|
January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo
Hayley Ma, Bao Nguyen, Li Li, et al.
American Journal of Clinical Pathology
|
February 17, 2012
Clinical and pathologic features of secondary acute promyelocytic leukemia
Amy S Duffield, Joseph Aoki, Mark Levis, et al.
Blood
|
March 31, 2005
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
Mark Levis, Kathleen M Murphy, Rosalyn Pham, et al.
The Journal of Molecular Diagnostics : JMD
|
April 23, 2003
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
Kathleen M Murphy, Mark Levis, Michael J Hafez, et al.
Blood
|
January 17, 2004
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
B Douglas Smith, Mark Levis, Miloslav Beran, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 92) with videos related to
Sort By:
Page
of 10
Blood
|
January 26, 2011
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato, Xiaochuan Yang, Steven Knapper, et al.
Leukemia & Lymphoma
|
September 28, 2011
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia
Michael W Evans, Anthony D Sung, Ivana Gojo, et al.
British Journal of Haematology
|
August 10, 2007
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells
Kyu-Tae Kim, Kristin Baird, Sean Davis, et al.
British Journal of Haematology
|
March 16, 2007
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells
Li Li, Obdulio Piloto, Kyu-Tae Kim, et al.
Signal Transduction and Targeted Therapy
|
May 24, 2021
FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
Ruiqi Zhu, Li Li, Bao Nguyen, et al.
Blood
|
January 11, 2014
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo
Hayley Ma, Bao Nguyen, Li Li, et al.
American Journal of Clinical Pathology
|
February 17, 2012
Clinical and pathologic features of secondary acute promyelocytic leukemia
Amy S Duffield, Joseph Aoki, Mark Levis, et al.
Blood
|
March 31, 2005
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
Mark Levis, Kathleen M Murphy, Rosalyn Pham, et al.
The Journal of Molecular Diagnostics : JMD
|
April 23, 2003
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay
Kathleen M Murphy, Mark Levis, Michael J Hafez, et al.
Blood
|
January 17, 2004
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
B Douglas Smith, Mark Levis, Miloslav Beran, et al.
Page
of 10